Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.31 +6.5%	$2.47	$1.28 ▼ $7.85	$253.84M	1.3	1.15 million shs	1.96 million shs
ARTV Artiva Biotherapeutics	$2.88 +4.0%	$2.34	$1.47 ▼ $17.31	$70.35M	N/A	93,754 shs	50,086 shs
NMRA Neumora Therapeutics	$1.62 -1.2%	$1.38	$0.61 ▼ $17.19	$262.35M	2.91	937,119 shs	338,797 shs
VOR Vor Biopharma	$2.17	$1.78	$0.13 ▼ $3.29	$274.90M	2.06	7.88 million shs	2.86 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-5.33%	-9.41%	+9.48%	-60.91%
ARTV Artiva Biotherapeutics	0.00%	+4.73%	-16.28%	+47.69%	-71.40%
NMRA Neumora Therapeutics	0.00%	-0.61%	-29.26%	+138.34%	-86.63%
VOR Vor Biopharma	0.00%	+1.40%	0.00%	+1,128.77%	+117.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.5978 of 5 stars	3.4	3.0	2.6	2.5	0.0
ARTV Artiva Biotherapeutics	2.8105 of 5 stars	3.5	0.0	1.6	2.5	1.3
NMRA Neumora Therapeutics	1.9347 of 5 stars	3.1	3.0	0.0	2.5	0.6
VOR Vor Biopharma	1.9391 of 5 stars	3.3	0.0	1.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.75	Moderate Buy	$12.50	441.13% Upside
ARTV Artiva Biotherapeutics	3.00	Buy	$17.00	490.28% Upside
NMRA Neumora Therapeutics	2.22	Hold	$7.14	340.92% Upside
VOR Vor Biopharma	2.56	Moderate Buy	$6.07	179.57% Upside

Current Analyst Ratings Breakdown

Latest ARTV, ANNX, NMRA, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/14/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
ARTV Artiva Biotherapeutics	$250K	281.43	N/A	N/A	$7.68 per share	0.38
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.29	0.00	N/A	N/A	N/A	-70.04%	-57.67%	N/A
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	11/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.57	0.00	N/A	N/A	N/A	-98.95%	-87.68%	11/11/2025 (Estimated)
VOR Vor Biopharma	N/A	-$13.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARTV, ANNX, NMRA, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.67	5.67
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
NMRA Neumora Therapeutics	0.11	10.54	10.54
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
ARTV Artiva Biotherapeutics	N/A
NMRA Neumora Therapeutics	47.65%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	12.67%
ARTV Artiva Biotherapeutics	21.40%
NMRA Neumora Therapeutics	26.80%
VOR Vor Biopharma	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.89 million	95.96 million	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
NMRA Neumora Therapeutics	108	161.95 million	118.54 million	Optionable
VOR Vor Biopharma	140	126.68 million	65.45 million	Not Optionable

ARTV, ANNX, NMRA, and VOR Headlines

Recent News About These Companies

Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2025 | finanznachrichten.de

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 19, 2025 | marketbeat.com

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright

August 19, 2025 | americanbankingnews.com

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 | globenewswire.com

Analysts Set Expectations for Vor Biopharma FY2028 Earnings

August 17, 2025 | marketbeat.com

Wedbush Brokers Boost Earnings Estimates for Vor Biopharma

August 17, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Vor Biopharma

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC Wainwright

August 16, 2025 | marketbeat.com

Wedbush Comments on Vor Biopharma's Q3 Earnings (NYSE:VOR)

August 16, 2025 | americanbankingnews.com

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13, 2025 | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13, 2025 | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13, 2025 | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025 | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2025 | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV, ANNX, NMRA, and VOR Company Descriptions

Annexon NASDAQ:ANNX

$2.31 +0.14 (+6.45%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.01 (-0.43%)

As of 08/22/2025 07:52 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Artiva Biotherapeutics NASDAQ:ARTV

$2.88 +0.11 (+3.97%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.00 (+0.17%)

As of 08/22/2025 05:23 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Neumora Therapeutics NASDAQ:NMRA

$1.62 -0.02 (-1.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.02 (+1.23%)

As of 08/22/2025 07:57 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Vor Biopharma NYSE:VOR

$2.17 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.19 +0.02 (+1.15%)

As of 08/22/2025 07:53 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time